Abstract
Recent genetics and genomics studies of prostate cancer have helped to clarify the genetic basis of this common but complex disease. Genome-wide studies have detected numerous variants associated with disease as well as common gene fusions and expression 'signatures' in prostate tumours. On the basis of these results, some advocate gene-based individualized screening for prostate cancer, although such testing might only be worthwhile to distinguish disease aggressiveness. Lessons learned from these studies provide strategies for further deciphering the genetic causes of prostate cancer and other diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schaid, D. J. The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet. 13 (Suppl. 1), 103–121 (2004).
Witte, J. S. Multiple prostate cancer risk variants on 8q24. Nature Genet. 39, 579–580 (2007).
Gudmundsson, J. et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nature Genet. 39, 631–637 (2007).
Haiman, C. A. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nature Genet. 39, 638–644 (2007).
Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nature Genet. 39, 870–874 (2007).
Gudmundsson, J. et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nature Genet. 39, 977–983 (2007).
Duggan, D. et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl Cancer Inst. 99, 1836–1844 (2007).
Gudmundsson, J. et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nature Genet. 40, 281–283 (2008).
Thomas, G. et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nature Genet. 40, 310–315 (2008).
Eeles, R. A. et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nature Genet. 40, 316–321 (2008).
Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
Tomlins, S. A. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595–599 (2007).
Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nature Rev. Cancer 8, 497–511 (2008).
Easton, D. F., Schaid, D. J., Whittemore, A. S. & Isaacs, W. J. Where are the prostate cancer genes? — A summary of eight genome wide searches. Prostate 57, 261–269 (2003).
Risch, N. & Merikangas, K. The future of genetic studies of complex human diseases. Science 273, 1516–1517 (1996).
Jorgenson, E. & Witte, J. S. Genome-wide association studies of cancer. Future Oncol. 3, 419–427 (2007).
Witte, J. S., Elston, R. C. & Schork, N. J. Genetic dissection of complex traits. Nature Genet. 12, 355–356 (1996).
Amundadottir, L. T. et al. A common variant associated with prostate cancer in European and African populations. Nature Genet. 38, 652–658 (2006).
Freedman, M. L. et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc. Natl Acad. Sci. USA 103, 14068–14073 (2006).
Severi, G. et al. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case–control study. Cancer Epidemiol. Biomarkers Prev. 16, 610–612 (2007).
Schumacher, F. R. et al. A common 8q24 variant in prostate and breast cancer from a large nested case–control study. Cancer Res. 67, 2951–2956 (2007).
Wang, L. et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res. 67, 2944–2950 (2007).
Suuriniemi, M. et al. Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol. Biomarkers Prev. 16, 809–814 (2007).
Zheng, S. L. et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J. Natl Cancer Inst. 99, 1525–1533 (2007).
Cheng, I. et al. 8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur. J. Hum. Genet. 16, 496–505 (2008).
Haiman, C. A. et al. A common genetic risk factor for colorectal and prostate cancer. Nature Genet. 39, 954–956 (2007).
Zanke, B. W. et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nature Genet. 39, 989–994 (2007).
Ghoussaini, M. et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J. Natl Cancer Inst. 100, 962–966 (2008).
Kiemeney, L. A. et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nature Genet. 40, 1307– 1312 (2008).
Sun, J. et al. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate 68, 691–697 (2008).
Beke, L., Nuytten, M., Van Eynde, A., Beullens, M. & Bollen, M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 26, 4590–4595 (2007).
Buckland, P. R. et al. Strong bias in the location of functional promoter polymorphisms. Hum. Mutat. 26, 214–223 (2005).
Sun, C. et al. TMPRSS2–ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27, 5348–5353 (2008).
Laxman, B. et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68, 645–649 (2008).
Attard, G. et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br. J. Cancer 99, 314–320 (2008).
Kote-Jarai, Z. et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol. Biomarkers Prev. 17, 2052–2061 (2008).
Zheng, S. L. et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 358, 910–919 (2008).
Ware, J. H. The limitations of risk factors as prognostic tools. N. Engl. J. Med. 355, 2615–2617 (2006).
Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Rev. Cancer 8, 268–278 (2008).
Mehra, R. et al. Characterization of TMPRSS2–ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 68, 3584–3590 (2008).
Setlur, S. R. et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J. Natl Cancer Inst. 100, 815–825 (2008).
Mucci, L. A. et al. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol. Biomarkers Prev. 17, 1682–1688 (2008).
Cheville, J. C. et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J. Clin. Oncol. 26, 3930–3936 (2008).
Fan, C. et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560–569 (2006).
Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008).
Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).
Chen, G. K. & Witte, J. S. Enriching the analysis of genomewide association studies with hierarchical modeling. Am. J. Hum. Genet. 81, 397–404 (2007).
Acknowledgements
Thanks to E. Jorgenson, I. Cheng and the anonymous referees for comments on this article. This work was supported by National Institutes of Health grants CA88164 and CA127298.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Related links
Glossary
- Admixture study
-
An approach for localizing genetic regions that might contain causal variants by correlating the level of individuals' admixture with disease. This type of analysis requires fewer markers than GWA studies, but necessitates a recently admixed population and variation in disease rates across ancestral populations.
- Area under the receiver operating characteristic curve
-
(AUC). The receiver operating characteristic curve for a predictor (for example, a genetic test) plots the proportion of cases correctly identified by the test versus the proportion of controls incorrectly classified as cases. The AUC indicates the probability that a factor (for example, a genotype) will predict a higher risk of disease in a randomly selected case than in a control.
- Cancer outlier profile analysis
-
(COPA). A method for detecting gene expression pattern outliers in subsets of samples. It is used to distinguish potential oncogenic chromosomal changes.
- Expression array study
-
An examination of the expression of all known genes. This type of analysis is commonly used to determine profiles or 'signatures' of overexpressed and underexpressed genes in diseased versus normal samples.
- Genome-wide association (GWA) study
-
An investigation of the association between common genetic variation and disease. This type of analysis requires a dense set of markers (for example, SNPs) that capture a substantial proportion of common variation across the genome, and large numbers of study subjects.
- Linkage analysis
-
A method for localizing chromosomal regions that harbour causal variants by studying the co-segregation of genetic makers and disease within families. When a marker is commonly observed with the disease, the causal variant might be in the general proximity of the marker.
- Negative predictive value
-
(NPV). The probability that an individual with a negative screening test is truly negative (for example, unaffected).
- Population attributable risk
-
(PAR). The disease incidence in a population that is attributable to a particular risk factor. GWA studies commonly report the PAR percentage to estimate what proportion of the disease is explained by associated variants.
- Positive predictive value
-
(PPV). Measures how well a screening or diagnostic test distinguishes true positives: it is the probability that an individual who tests positive is truly positive (for example, affected).
Rights and permissions
About this article
Cite this article
Witte, J. Prostate cancer genomics: towards a new understanding. Nat Rev Genet 10, 77–82 (2009). https://doi.org/10.1038/nrg2507
Issue Date:
DOI: https://doi.org/10.1038/nrg2507
This article is cited by
-
Familiäres Prostatakarzinom und genetische Prädisposition
Der Urologe (2021)
-
Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines
World Journal of Urology (2019)
-
Genome-wide detection of allelic genetic variation to predict biochemical recurrence after radical prostatectomy among prostate cancer patients using an exome SNP chip
Journal of Cancer Research and Clinical Oncology (2015)
-
Association between Tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis
Diagnostic Pathology (2014)
-
An updated meta-analysis on association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and cancer risk
Tumor Biology (2014)